A Clinical Study to Evaluate the Effect of Hepatic Impairment on the Single-Dose Pharmacokinetics of MK-1084

The main inclusion criteria include but are not limited to:

All participants:

• Has a body mass index (BMI) between 18.0 and 42.0 kg/m^2

Participants with hepatic impairment (HI):

• Has a diagnosis of chronic, stable hepatic insufficiency at screening with features of cirrhosis

Healthy volunteers:

• Is medically healthy with no clinically significant medical history

The main exclusion criteria include but are not limited to:

All participants:

• Has a history of gastrointestinal disease which may affect food and drug absorption
• Has a history of cancer (malignancy)
• Has a positive result for human immunodeficiency virus (HIV)
• Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing

Participants with HI:

• Has had severe complications of liver disease within the preceding 3 months of screening
• Has a history of recent (within 3 months prior to screening) variceal bleeds
• Has evidence of hepatorenal syndrome
• Is not in sufficient health, with regard to stability of HI, to undergo participation in the study with anticipated survival of < 3 months
• Has a history of liver or other solid organ transplantation
• Has an active infection requiring systemic therapy
• Requires paracentesis more often than 2 times per month
• Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting
• Has received antiviral and/or immune modulating therapy for hepatitis B virus (HBV) or hepatitis C virus (HCV) within 90 days prior to dosing
• Is using HIV protease inhibitors
• Is positive for Hepatitis B surface antigen (HBsAg)
• Is positive for HCV

Healthy volunteers:

• Has positive results for HBsAg or HCV